MarketsNotableReported
6.8
US Stocks Slip Ahead of Inflation Data; J&J Slides on Weak Devices Results
InfoMoney·US·1 day ago
Johnson & Johnson's CFO indicated the company is inclined to separate its hip and knee implant business, a move that would reshape its portfolio. The decision is not final, and details remain uncertain. This signals a strategic shift that could impact J&J's stock and the medical devices sector.